The global generic drugs market reached a value of US$ 386 Billion in 2020.
A generic drug is a medicine that contains the same active ingredient and has an equivalent therapeutic effect as the branded drug. It is also identical in terms of safety, quality, dosage, strength, route of administration, intended use, effect, form, quality and side effects. These medications can be produced only after the patent expiration of the brand-name drug. As compared to branded drugs, the production of generics costs much less as it does not require the repetition of clinical (human) and animal studies to demonstrate the effectiveness and safety of the medicine. Due to a reduction in the upfront cost of research, generics are typically sold at a substantially lower price in the market.
Market Trends: Due to an aging population and increasing incidences of chronic diseases, governments of developed countries have been making efforts to reduce healthcare costs by promoting the production of generics. Whereas, in developing countries, affordability and accessibility are some of the primary issues faced by the healthcare industry. To address these problems, governments and other regulatory bodies have been encouraging manufacturers to introduce effective generic drugs. However, despite the rapid patent expiry of branded drugs, there has been a shortage of generics. This situation is currently being rectified by various initiatives taken by hospitals, institutions and other organizations across the globe. For instance, in 2018, a coalition of seven hospitals and three philanthropies in the US announced that they would be addressing drug shortages and the high cost of essential medications by launching a generic drug company, named Civica Rx. The company is producing 14 short-supply, FDA-approved drugs that have been available in the market since the beginning of 2019. Other than this, in 2018, the United States Food and Drug Administration (USFDA) created policies to make the process of market entry and generic approval more efficient. It issued guidance documents for the development of both hard-to-copy drug categories and specific complex drugs. Looking forward, the analyst expects the global generic drugs market to exhibit moderate growth during the next five years.
Breakup by Therapy Area: Central Nervous System Cardiovascular Dermatology Genitourinary/Hormonal Respiratory Rheumatology Diabetes Oncology Others Cardiovascular diseases (CVDs) are the leading therapy area, accounting for the majority of the total market, on account of the increasing cases of CVDs as a result of unhealthy eating habits and sedentary lifestyles.
Breakup by Drug Delivery: Oral Injectables Dermal/Topical Inhalers Currently, oral medicines are the most preferred product, owing to the convenience attached to their administration, which requires minimal to no medical assistance.
Breakup by Distribution Channel: Retail Pharmacies Hospital Pharmacies At present, the majority of the generics are distributed through retail pharmacy stores as most generic drugs are over the counter (OTC) medicines that can be bought without a prescription.
Regional Insights: United States China Brazil Germany France India United Kingdom Japan Canada Italy Others On a regional basis, the United States represents the biggest market, accounting for the largest market share. This growth is led by numerous initiatives by the US Government to improve generic drug manufacturing and access in the country.
Competitive Landscape: The market is fragmented in nature with the presence of various small and large manufacturers. Some of the leading players operating in the market include Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited, and Aspen Pharmacare Holdings Limited.
Key Questions Answered in This Report: How has the market performed so far and how will it perform in the coming years? What are the key regional markets? What has been the impact of COVID-19 on the global generic drugs market? What are the major drug delivery segments? What are the key therapy areas? What are the major distribution channels? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the industry and who are the key players? What is the degree of competition in the industry? What are the profit margins in the industry? What are the key requirements for setting up a manufacturing plant? How are generic drugs manufactured? What are the various unit operations involved in a manufacturing plant? What is the total size of land required for setting up a manufacturing plant? What are the machinery requirements for setting up a manufacturing plant? What are the raw material requirements for setting up a manufacturing plant? What are the packaging requirements for generic drugs? What are the transportation requirements for generic drugs? What are the utility requirements for setting up a manufacturing plant? What are the manpower requirements for setting up a manufacturing plant? What are the infrastructure costs for setting up a manufacturing plant? What are the capital costs for setting up a manufacturing plant? What are the operating costs for setting up a manufacturing plant? What will be the income and expenditures for a manufacturing plant? What is the time required to break-even?
Our reports have been used by over 10K customers, including:
Report Scope This report discusses the implications of all the above-mentioned trends in the context of the current size and growth of the market for generic drugs, both in global terms and broken down by the most important national markets.The nature and structure of the generic drug industry is discussed, with profiles...
Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) - Drugs in Development, 2021 Summary Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity...
The Global Telmisartan Market size is expected to reach $4 billion by 2026, rising at a market growth of 5.8% CAGR during the forecast period. Telmisartan refers to an angiotensin receptor blocker (ARB) utilized alone or combined with other agents in order to treat stroke management, cardiac arrest, and hypertension. Telmisartan is available...
285 pages •
By Global Industry Analysts
• May 2021
- Global Generic Drugs Market to Reach US$536.4 Billion by the Year 2027
- Amid the COVID-19 crisis, the global market for Generic Drugs estimated at US$365.9 Billion in the year 2020, is projected to reach a revised size of US$536.4 Billion by 2027, growing at a CAGR of 5.6% over...
Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) - Drugs in Development, 2021 Summary Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) - Drugs in Development, 2021 provides...
Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021 Summary Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021 provides...
Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 220.127.116.11) - Drugs in Development, 2021 Summary Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 18.104.22.168) - Drugs...
120 pages •
By Infiniti Research Limited
• Apr 2021
Analytical instrument market in US 2021-2025 The analyst has been monitoring the analytical instrument market in the US and it is poised to grow by $ 5.57 bn during 2021-2025, progressing at a CAGR of almost 3% during the forecast period. Our report on analytical instrument market in the US provides a holistic analysis, market size and...
Generic injectables are bio-equivalents of their branded counterparts which are not protected by drug patents. They are as safe and effective as the innovator drugs since they have similar active ingredient, dosage, strength, quality, form, etc. Although the manufacturing of generic injectables is complex, their R&D...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.